Analyst Ratings For Alexion Pharmaceuticals (NASDAQ:ALXN)
Today, Stifel Nicolaus reiterated its Buy rating on Alexion Pharmaceuticals (NASDAQ:ALXN) with a price target of $151.00.
Some recent analyst ratings include
- 2/9/2018-Stifel Nicolaus Reiterated Rating of Buy.
- 2/5/2018-Evercore ISI Upgrade from a “In-Line ” rating to a ” Outperform” rating.
- 1/18/2018-Credit Suisse Group Reiterated Rating of Outperform .
Recent Insider Trading Activity For Alexion Pharmaceuticals (NASDAQ:ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) has insider ownership of 4.35% and institutional ownership of 94.04%.
- On 2/8/2018 Heidi L Wagner, SVP, sold 1,774 with an average share price of $116.31 per share and the total transaction amounting to $206,333.94.
- On 2/8/2018 John B Moriarty, EVP, sold 3,363 with an average share price of $115.70 per share and the total transaction amounting to $389,099.10.
- On 2/8/2018 Ludwig Hantson, CEO, sold 13,245 with an average share price of $116.31 per share and the total transaction amounting to $1,540,525.95.
- On 2/8/2018 Paul J Clancy, CFO, sold 6,079 with an average share price of $116.31 per share and the total transaction amounting to $707,048.49.
- On 2/5/2018 Heidi L Wagner, SVP, sold 655 with an average share price of $117.26 per share and the total transaction amounting to $76,805.30.
- On 2/5/2018 John B Moriarty, EVP, sold 1,261 with an average share price of $117.26 per share and the total transaction amounting to $147,864.86.
- On 1/2/2018 Ludwig Hantson, CEO, sold 2,553 with an average share price of $121.63 per share and the total transaction amounting to $310,521.39.
Recent Trading Activity for Alexion Pharmaceuticals (NASDAQ:ALXN)
Shares of Alexion Pharmaceuticals closed the previous trading session at 105.90 down -2.57 2.37% with 1651845 shares trading hands.
